Company Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis.
The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Douglas Love |
Contact Details
Address: 1400 Sierra Point Parkway, Building C Brisbane, California 94005 United States | |
| Phone | 650 822 5500 |
| Website | annexonbio.com |
Stock Details
| Ticker Symbol | ANNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001528115 |
| CUSIP Number | 03589W102 |
| ISIN Number | US03589W1027 |
| Employer ID | 27-5414423 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas E. Love Esq., J.D. | Chief Executive Officer, President and Director |
| Dr. Ted Yednock Ph.D. | Executive Vice President, Chief Innovation Officer and Chairman of the Scientific Advisory Board |
| Dr. Jamie Dananberg M.D. | Executive Vice President and Chief Medical Officer |
| Jennifer Lew CPA | Executive Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer and Executive Vice President |
| Michael Overdorf M.B.A. | Executive Vice President and Chief Business Officer |
| Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine |
| Shikhar Agarwal M.B.A. | Senior Vice President and Head of Commercial |
| Dr. Sunil Mehta Pharm.D. | Senior Vice President of Medical Affairs |
| Dr. Lloyd Clark M.D. | Senior Vice President of Ophthalmology Strategy and Innovation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 2, 2026 | 144 | Filing |